Randomized, Open Label, Phase 3 Clinical Study To Evaluate The Effect Of The Addition Of CP-751,871 To Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer.

Trial Profile

Randomized, Open Label, Phase 3 Clinical Study To Evaluate The Effect Of The Addition Of CP-751,871 To Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2014

At a glance

  • Drugs Figitumumab (Primary) ; Cisplatin; Gemcitabine
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms ADVIGO
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Apr 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 11 Mar 2010 Planned initiation date changed from 1 Apr 2010 to 1 Jul 2010 as reported by ClinicalTrials.gov.
    • 11 Mar 2010 Planned end date changed from 1 Apr 2014 to 1 May 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top